Cite

HARVARD Citation

    Silberstein, S. et al. (2019). Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache. 59 (6), pp. 880-890. [Online]. 
  
Back to record